Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Peak-time Sales of Radicut, Zyprexa Expected to Top \10 Bil.
June 4, 2001
- NEW PRODUCTS NEWS IN BRIEF
June 4, 2001
- Chuikyo to Review NHI Pricing Rule
June 4, 2001
- WORLD NEWS IN BRIEF
June 4, 2001
- EMA Demands Acceptance of "Moth-eaten Applications"
June 4, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 4, 2001
- Pricing Organization Accepts Eli Lilly Japan's Objection
June 4, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 4, 2001
- REGULATORY NEWS IN BRIEF
June 4, 2001
- DIAGNOSTIC NEWS IN BRIEF
June 4, 2001
- Kowa Licenses Antidiabetic Drug from Roche
June 4, 2001
- MEDICAL DEVICE NEWS IN BRIEF
June 4, 2001
- Life-cycle Management of Adalat Is Successful: Dr Ebsworth of Bayer
June 4, 2001
- Mitsubishi-Tokyo, Welfide Sign Merger Contract
June 4, 2001
- FY2000 Business Reports Show Large Gap between Poor and Excellent Performers
June 4, 2001
- BULLETIN
June 4, 2001
- EPS Goes Public, First Listed CRO in Japan
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -4-
June 4, 2001
- BUSINESS NEWS IN BRIEF
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -5-
June 4, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…